Larotrectinib - Generic Drug Details
✉ Email this page to a colleague
Summary for larotrectinib
| International Patents: | 129 |
| US Patents: | 10 |
| Tradenames: | 1 |
| Applicants: | 2 |
| NDAs: | 2 |
| Finished Product Suppliers / Packagers: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 20 |
| Clinical Trials: | 2 |
| Patent Applications: | 30 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for larotrectinib |
| What excipients (inactive ingredients) are in larotrectinib? | larotrectinib excipients list |
| DailyMed Link: | larotrectinib at DailyMed |
Recent Clinical Trials for larotrectinib
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Fujian Medical University | PHASE4 |
| Sun Yat-sen University | PHASE2 |
| Theodore Laetsch | Phase 2 |
US Patents and Regulatory Information for larotrectinib
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bayer Healthcare | VITRAKVI | larotrectinib sulfate | SOLUTION;ORAL | 211710-001 | Nov 26, 2018 | RX | Yes | Yes | 11,337,967 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Bayer Healthcare | VITRAKVI | larotrectinib sulfate | SOLUTION;ORAL | 211710-001 | Nov 26, 2018 | RX | Yes | Yes | 9,447,104 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Bayer Healthcare | VITRAKVI | larotrectinib sulfate | SOLUTION;ORAL | 211710-001 | Nov 26, 2018 | RX | Yes | Yes | 10,799,505 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Bayer Hlthcare | VITRAKVI | larotrectinib sulfate | CAPSULE;ORAL | 210861-002 | Nov 26, 2018 | RX | Yes | Yes | 10,285,993 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Bayer Hlthcare | VITRAKVI | larotrectinib sulfate | CAPSULE;ORAL | 210861-002 | Nov 26, 2018 | RX | Yes | Yes | 9,127,013 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
